Anticancer Chemosensitization and Radiosensitization by the Novel Poly(ADP-ribose) Polymerase-1 Inhibitor AG14361
Open accessThe DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Poly(ADP-ribose) polymerase-1 (PARP-1) facilitates the repair of DNA strand breaks. Inhibiting PARP-1 increases the cytotoxicity of DNA-damaging chemotherapy and radiation therapy in vitro. Because classical PARP-1 inhibitors have limited clinical utility, we investigated whether AG14361, a novel potent PARP-1 inhibitor (inhibition constant <5 nM), enhances the effects of chemotherapy and radiation therapy in human cancer cell cultures and xenografts. METHODS: The effect of AG14361 on the antitumor activity of the DNA alkylating agent temozolomide, topoisomerase I poisons topotecan or irinotecan, or x-irradiation or gamma-radiation was investigated in human cancer cell lines A549, LoVo, and SW620 by proliferation and survival assays and in xenografts in mice by tumor volume determination. The specificity of AG14361 for PARP-1 was investigated by microarray analysis and by antiproliferation and acute toxicity assays in PARP-1-/- and PARP-1+/+ cells and mice. After intraperitoneal administration, the concentration of AG14361 was determined in mouse plasma and tissues, and its effect on PARP-1 activity was determined in tumor homogenates. All statistical tests were two-sided. RESULTS: AG14361 at 0.4 micro M did not affect cancer cell gene expression or growth, but it did increase the antiproliferative activity of temozolomide (e.g., in LoVo cells by 5.5-fold, 95% confidence interval [CI] = 4.9-fold to 5.9-fold; P =.004) and topotecan (e.g., in LoVo cells by 1.6-fold, 95% CI = 1.3-fold to 1.9-fold; P =.002) and inhibited recovery from potentially lethal gamma-radiation damage in LoVo cells by 73% (95% CI = 48% to 98%). In vivo, nontoxic doses of AG14361 increased the delay of LoVo xenograft growth induced by irinotecan, x-irradiation, or temozolomide by two- to threefold. The combination of AG14361 and temozolomide caused complete regression of SW620 xenograft tumors. AG14361 was retained in xenografts in which PARP-1 activity was inhibited by more than 75% for at least 4 hours. CONCLUSION: AG14361 is, to our knowledge, the first high-potency PARP-1 inhibitor with the specificity and in vivo activity to enhance chemotherapy and radiation therapy of human cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, PARP inhibitors enhanced the anticancer activity of chemoradiation in CRC cell lines in vitro and in vivo [136,137,138].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [136]
Citations
Cites
Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination
Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., et al. (1998) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998003254 · Cited by 15,715 · cited 1×
“Crystals had a space group of P212121, with a 59.09 A , b 64.35 A , and c 97.38 A , and a resolution of 2.15 A . The structure was solved from a previously determined structure by use of 2Fobs ‐ Fcalc and Fobs ‐Fcalc maps and refinement ( 24 ), where Fobs is the amplitude of the experimentally measured structu…”
MethodInfluentialNew Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1107 · Cited by 9,766 · cited 1×
“After 5 days of culture, these cells were fixed with 10% trichloroacetic acid and stained with sulforhodamine B ( 28 ).”
MethodMohamadi, F., Richards, N. G. J., Guida, W. C., Liskamp, R., Lipton, M., Caufield, C., Chang, G., Hendrickson, T., & Still, W. C. (1990) · Journal of Computational Chemistry · doi:10.1002/jcc.540110405 · Cited by 3,757 · cited 1×
“Molecular modeling of AG14361 with a chimeric human PARP-1 model, created from the co-crystal structure of AG14361 with the catalytic domain of chicken PARP-1 (humanized by changing residue 763 from glutamine to glutamate), used MacroModel version 5.5 ( 25 ).”
MethodInfluentialExpression monitoring by hybridization to high-density oligonucleotide arrays
Lockhart, D. J., Dong, H., Byrne, M. C., Follettie, M. T., Gallo, M. V., Chee, M. S., Mittmann, M., Wang, C., Kobayashi, M., Norton, H., et al. (1996) · Nature Biotechnology · doi:10.1038/nbt1296-1675 · Cited by 2,840
International Journal of Oncology
(2026) · International Journal of Oncology · doi:10.3892/ijo · Cited by 2,331
In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain
Chen, T. R. (1977) · Experimental Cell Research · doi:10.1016/0014-4827(77)90089-1 · Cited by 1,700
The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors
Virág, L., & Szabó, C. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.3.375 · Cited by 1,373 · cited 1×
“Although researchers in a limited number of in vivo anticancer studies of second-generation PARP-1 inhibitors in combination with cytotoxic agents have observed increased survival compared with chemotherapy alone (4,18,40), most in vivo investigations of secondgeneration PARP-1 inhibitors have focused on protecting no…”
BackgroundSISSAOUI, M. (2018) · Archives of Clinical Microbiology · doi:10.4172/1989-8436-c3-011 · Cited by 1,349
Horder, & Harnett, W. L. (1941) · BMJ · doi:10.1136/bmj.1.4186.493 · Cited by 1,314
Role of poly(ADP-ribose) formation in DNA repair
Satoh, M. S., & Lindahl, T. (1992) · Nature · doi:10.1038/356356a0 · Cited by 1,174 · cited 2×
“Evidence from both inhibitor ( 7 ,8) and molecular genetic (9 ‐11) studies indicates that inhibiting PARP-1-mediated DNA repair increases the cytotoxicity of DNA-damaging cancer therapeutics.”
BackgroundRequirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells
de Murcia, J. M., Niedergang, C., Trucco, C., Ricoul, M., Dutrillaux, B., Mark, M., Oliver, F. J., Masson, M., Dierich, A., LeMeur, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7303 · Cited by 1,056
Teratocarcinomas and Embryonic Stem Cells: A Practical Approach
Robertson, E. J., & Beddington, R. (1988) · Development · doi:10.1242/dev.102.1.3 · Cited by 1,030
Genome-wide expression monitoring in Saccharomyces cerevisiae
Wodicka, L., Dong, H., Mittmann, M., Ho, M.-H., & Lockhart, D. J. (1997) · Nature Biotechnology · doi:10.1038/nbt1297-1359 · Cited by 973 · cited 1×
“RNA was hybridized on human Hu6800 high-density oligonucleotide arrays (Affymetrix, Santa Clara, CA), as previously described ( 29 ,30).”
MethodNewlands, E. S., Stevens, M. F. G., Wedge, S. R., Wheelhouse, R. T., & Brock, C. (1997) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(97)90019-0 · Cited by 817 · cited 1×
“Temozolomide alone at 68 mg/kg given daily for 5 days [approximately equivalent to the recommended schedule in patients of 200 mg/m2 per day ( 37 )] induced a tumor growth delay (time to RTV4) of 3 days (95% CI 0 to 6 days) for LoVo xenografts and 24 days (95% CI 16 to 32 days) for SW620 xenografts (Fig. 5, A and B).…”
BackgroundPoly(ADP-ribose) polymerase: a molecular nick-sensor
de Murcia, G., & de Murcia, J. M. (1994) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(94)90280-1 · Cited by 797
Novel inhibitors of poly(ADP-ribose) synthetase
Purnell, M. R., & Whish, W. J. (1980) · Biochemical Journal · doi:10.1042/bj1850775 · Cited by 527
Base Excision Repair Is Impaired in Mammalian Cells Lacking Poly(ADP-ribose) Polymerase-1
Dantzer, F., de la Rubia, G., Ménissier-de Murcia, J., Hostomsky, Z., de Murcia, G., & Schreiber, V. (2000) · Biochemistry · doi:10.1021/bi0003442 · Cited by 505 · cited 1×
“PARP-1 interacts with other components of the base excision repair complex, and cells lacking PARP-1 activity are deficient in base excision repair ( 3 ).”
BackgroundSpecific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase.
Banasik, M., Komura, H., Shimoyama, M., & Ueda, K. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45983-2 · Cited by 476
Regional and strain-specific gene expression mapping in the adult mouse brain
Sandberg, R., Yasuda, R., Pankratz, D. G., Carter, T. A., Del Rio, J. A., Wodicka, L., Mayford, M., Lockhart, D. J., & Barlow, C. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.20.11038 · Cited by 446 · cited 1×
“RNA was hybridized on human Hu6800 high-density oligonucleotide arrays (Affymetrix, Santa Clara, CA), as previously described (29, 30 ).”
MethodClinical Relevance of MGMT in the Treatment of Cancer
Gerson, S. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.110 · Cited by 428 · cited 1×
“Unlike ATase inhibitors, which can only sensitize cells pro ficient in mismatch repair ( 44 ), AG14361 increased the activity of temozolomide in mismatch repair-deficient LoVo cells in vitro and in vivo.”
BackgroundSmith, S. (2001) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)01780-1 · Cited by 314 · cited 1×
“It is the first and most extensively characterized member of an expanding family of PARP enzymes ( 1 ).”
BackgroundARCON: a novel biology-based approach in radiotherapy
Kaanders, J. H., Bussink, J., & van der Kogel, A. J. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00929-4 · Cited by 256 · cited 1×
“Nicotinamide (a weak PARP-1 inhibitor) similarly inhibits contraction of vascular smooth muscle in tumors by a mechanism that does not involve nitric oxide release or Ca2 signaling (57,58); nicotinamide is in advanced clinical trials to evaluate its ability to increase sensitivity to radiation therapy ( 59 ).”
BackgroundMolinete, M., Vermeulen, W., Bürkle, A., Ménissier-de Murcia, J., Küpper, J. H., Hoeijmakers, J. H., & de Murcia, G. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05859.x · Cited by 244
Mendoza-Alvarez, H., & Alvarez-Gonzalez, R. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41568-2 · Cited by 227
Delaney, C. A., Wang, L. Z., Kyle, S., White, A. W., Calvert, A. H., Curtin, N. J., Durkacz, B. W., Hostomský, Z., & Newell, D. R. (2000) · PubMed · doi:10.25405/ncl.34597155 · Cited by 205
Self-citationMechanisms of carcinogenicity/chemotherapy by O6-methylguanine
Margison, G. P. (2002) · Mutagenesis · doi:10.1093/mutage/17.6.483 · Cited by 205 · cited 1×
“... of temozolomide in SW620 cells in vitro (Fig. 4, A), but the combination of AG14361 and temozolomide resulted in the complete regression of SW620 xenografts (Fig. 5, B). SW620 cells are hypersensitive to temozolomide by virtue of low ATase levels and mismatch repair proficiency (49,50), because resistance to DNA a…”
BackgroundWilliams, K. J., Telfer, B. A., Stratford, I. J., & Wedge, S. R. (2002) · British Journal of Cancer · doi:10.1038/sj....bjc.6600182 · Cited by 175 · cited 1×
“Because AG14361 doubled the radiation-induced tumor-growth delay, PARP-1 inhibition may be an effective alternative to other radiosensitization approaches, such as the use of bioreductively activated drugs (45,46) or the inactivation or inhibition of epidermal growth factor receptor tyrosine kinase (47, 48 ).”
BackgroundSelf-citationRole of Glutamic Acid 988 of Human Poly-ADP-ribose Polymerase in Polymer Formation
Marsischky, G. T., Wilson, B. A., & Collier, R. J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.7.3247 · Cited by 169
Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors
Tentori, L., Portarena, I., & Graziani, G. (2002) · Pharmacological Research · doi:10.1006/phrs.2001.0935 · Cited by 155 · cited 2×
“Although researchers in a limited number of in vivo anticancer studies of second-generation PARP-1 inhibitors in combination with cytotoxic agents have observed increased survival compared with chemotherapy alone ( 4 ,18,40), most in vivo investigations of secondgeneration PARP-1 inhibitors have focused on protecting…”
BackgroundTricyclic Benzimidazoles as Potent Poly(ADP-ribose) Polymerase-1 Inhibitors
Skalitzky, D. J., Marakovits, J. T., Maegley, K. A., Ekker, A., Yu, X.-H., Hostomsky, Z., Webber, S. E., Eastman, B. W., Almassy, R., Li, J., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0255769 · Cited by 152
Self-citationBowman, K. J., Newell, D. R., Calvert, A. H., & Curtin, N. J. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1555 · Cited by 144
Self-citationBowman, K., White, A., Golding, B., Griffin, R., & Curtin, N. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.670 · Cited by 142
Self-citationKoch, S. S. C., Thoresen, L. H., Tikhe, J. G., Maegley, K. A., Almassy, R. J., Li, J., Yu, X., Zook, S. E., Kumpf, R. A., Zhang, C., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020259n · Cited by 141
Self-citationFrom DNA damage and stress signalling to cell death : poly-ADP-ribosylation reactions
de MURCIA, G., & Shall, S. (2000) · Medical Entomology and Zoology · Cited by 134
Horsman, M. R. (1995) · Acta Oncologica · doi:10.3109/02841869509094031 · Cited by 126
Wedge, S. R., Porteous, J. K., & Newlands, E. S. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.485 · Cited by 123
DNA repair in resistance to alkylating anticancer drugs
Kaina, B., & Christmann, M. (2002) · Int. Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp40354 · Cited by 117
Taverna, P., Liu, L., Hwang, H.-S., Hanson, A. J., Kinsella, T. J., & Gerson, S. L. (2001) · Mutation Research/DNA Repair · doi:10.1016/s0921-8777(01)00076-3 · Cited by 113 · cited 1×
“Similar studies have shown that, whereas 3-aminobenzamide and another base excision repair inhibitor (methoxyamine) can sensitize mismatch repairdeficient cells to temozolomide (53, 54 ), 3-aminobenzamide is ineffective in cells that are hypersensitive to temozolomide because of low ATase activity and mismatch repair…”
Suto, M. J., Turner, W. R., Arundel-Suto, C. M., Werbel, L. M., & Sebolt, J. S. (1991) · PubMed · Cited by 112
Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development
(1992) · Springer eBooks · doi:10.1007/978-1-4615-3492-1 · Cited by 105
Ding, R., & Smulson, M. E. (1994) · PubMed · Cited by 97
Epidermal Growth Factor Receptor as a Genetic Therapy Target for Carcinoma Cell Radiosensitization
Lammering, G., Hewit, T. H., Hawkins, W. T., Contessa, J. N., Reardon, D. B., Lin, P.-S., Valerie, K., Dent, P., Mikkelsen, R. B., & Schmidt-Ullrich, R. K. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.12.921 · Cited by 96 · cited 1×
“Because AG14361 doubled the radiation-induced tumor-growth delay, PARP-1 inhibition may be an effective alternative to other radiosensitization approaches, such as the use of bioreductively activated drugs (45,46) or the inactivation or inhibition of epidermal growth factor receptor tyrosine kinase ( 47 ,48).”
BackgroundGriffin, R., Curtin, N. J., Newell, D. R., Golding, B. T., Durkacz, B. W., & Calvert, H. (1995) · Biochimie · doi:10.1016/0300-9084(96)88154-5 · Cited by 91
Self-citationTentori, L., Leonetti, C., Scarsella, M., d'Amati, G., Portarena, I., Zupi, G., Bonmassar, E., & Graziani, G. (2002) · Blood · doi:10.1182/blood.v99.6.2241 · Cited by 83 · cited 2×
“However, these compounds still lacked the potency and solubility for extensive preclinical evaluation, although a recent report ( 18 ) demonstrated that intracranial injection of NU1025 increased the temozolomide-induced survival of mice with brain lymphomas.”
Background(2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1163 · Cited by 81
Self-citationN-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea sensitivity in mismatch repair-defective human cells.
Aquilina, G., Ceccotti, S., Martinelli, S., Hampson, R., & Bignami, M. (1998) · PubMed · Cited by 74
Barendsen, G. W., Chris van, B. R. E. E., & Franken, N. A. P. (2001) · International Journal of Oncology · doi:10.3892/ijo.19.2.247 · Cited by 68
Weichselbaum, R. R., & Little, J. B. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.237 · Cited by 45
Middleton, M. R., Thatcher, N. J., McMurry, T. B. H., McElhinney, R. S., Donnelly, D. J., & Margison, G. P. (2002) · International Journal of Cancer · doi:10.1002/ijc.10532 · Cited by 43 · cited 1×
“The addition of AG14361 increased the antitumor activity of both irinotecan and fractionated x-irradiation approximately twofold in both LoVo and SW620 xenografts (Fig. 5). Alternative strategies to increase the antitumor activity of temozolomide by inhibiting the DNA repair protein O6-alkylguanine DNA alkyltransferas…”
BackgroundGrube, K., Küpper, J., & Bürkle, A. (1991) · Analytical Biochemistry · doi:10.1016/0003-2697(91)90015-l · Cited by 41
Raju, U., Gumin, G. J., & Tofilon, P. J. (1999) · Radiation Oncology Investigations · doi:10.1002/(sici)1520-6823(1999)7:3<145::aid-roi2>3.0.co;2-r · Cited by 38
The radiosensitizer nicotinamide inhibits arterial vasoconstriction
Hirst, D. G., Kennovin, G. D., & Flitney, F. W. (1994) · British Journal of Radiology · doi:10.1259/0007-1285-67-800-795 · Cited by 37 · cited 1×
“Nicotinamide (a weak PARP-1 inhibitor) similarly inhibits contraction of vascular smooth muscle in tumors by a mechanism that does not involve nitric oxide release or Ca2 signaling ( 57 ,58); nicotinamide is in advanced clinical trials to evaluate its ability to increase sensitivity to radiation therapy (59).”
BackgroundDMA repair mechanisms associated with cellular resistance to antitumor drugs
Barret, J.-M. M., & Hill, B. T. (1998) · Anti-Cancer Drugs · doi:10.1097/00001813-199802000-00001 · Cited by 36
Jung, S. C., Miranda, E. A., Murcia, J. M., Niedergang, C., Delarue, M. H., Schulz, G. E., & de MURCIA, G. (1994) · Journal of Molecular Biology · doi:10.1006/jmbi.1994.1709 · Cited by 28
Lunn, J., & Harris, A. L. (1988) · British Journal of Cancer · doi:10.1038/bjc.1988.8 · Cited by 25
Thomas, C. D., Stern, S., Chaplin, D. J., & Guichard, M. (1996) · Radiotherapy and Oncology · doi:10.1016/0167-8140(96)01734-3 · Cited by 18
Nicotinamide-inhibited vasoconstriction: lack of dependence on agonist signalling pathways
Burns, D., Ruddock, M. W., Walker, M. D., Allen, J. M., Kennovin, G. D., & Hirst, D. G. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00323-4 · Cited by 10
Effect of carbogen breathing on the pharmacodynamics of 5-fluorouracil in a murine colon carcinoma
Kamm, Y. J. L., Heerschap, A., & Wagener, D. J. T. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00063-0 · Cited by 9 · cited 1×
“AG14361 increased transient perfusion (Fig. 6), potentially altering the microdistribution and delivery of chemotherapeutic agents ( 56 ).”
BackgroundBerthet, N., Boturyn, D., & Constant, J. (1999) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.9.4.401 · Cited by 8
Analysis of Biological Molecules: An introduction to principles, instrumentation and techniques
Potter, G. W. H. (1994) · Cited by 5
Martin, D., Stolfi, R. L., Nord, L. D., & Colofiore, J. R. (1996) · Oncology Reports · doi:10.3892/or.3.2.317 · Cited by 4
Research works printed but not linked: 5
- Ding, 1994, Cancer Research, 54, 4627
- 1996, Oncology reports, 3, 317
- el-Said, 1999, Radiation oncology investigations, 7, 163, 10.1002/(sici)1520-6823(1999)7:3<163::aid-roi5>3.0.co;2-m · doi:10.1002/(sici)1520-6823(1999)7:3<163::aid-roi5>3.0.co;2-m
- Williams, 2002, British Journal of Cancer, 86, 1157, 10.1038/sj.bjc.6600182 · doi:10.1038/sj.bjc.6600182 · Paper page
- Aquilina, 1998, Cancer Research, 58, 135
Cited by
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Self-citationTriple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.66 · Cited by 3,079
Poly(ADP-ribose): novel functions for an old molecule
Schreiber, V., Dantzer, F., Ame, J.-C., & de Murcia, G. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1963 · Cited by 1,915
“PARP inhibitors have been shown to enhance the antiproliferative activity of the DNA-methylating agent temozolomide, ionizing radiation and the topoisomerase-I inhibitors topotecan and irinotecan, both in human cancer-cell culture and in xenografts in mic”
BackgroundAmé, J., Spenlehauer, C., & de Murcia, G. (2004) · BioEssays · doi:10.1002/bies.20085 · Cited by 1,459
“PARP involvement in both cell survival and cell death gives rise to an intense industrial effort to develop potent chemical inhibitors that, at the preclinical phase, are now able to cause a complete regression of xenograft tumors.((73)) Among the other members of the PARP family, the Tankyrase group, which is involve…”
BackgroundDNA damage response signaling pathways and targets for radiotherapy sensitization in cancer
Huang, R.-X., & Zhou, P.-K. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0150-x · Cited by 1,198
Metadata
- Authors
- Calabrese, C. R., Almassy, R., Barton, S., Batey, M. A., Calvert, A. H., Canan-Koch, S., Durkacz, B. W., Hostomsky, Z., Kumpf, R. A., Kyle, S., Li, J., Maegley, K., Newell, D. R., Notarianni, E., Stratford, I. J., Skalitzky, D., Thomas, H. D., Wang, L.-Z., Webber, S. E., Williams, K. J., & Curtin, N. J.
- Affiliations
- Newcastle University (GB)
- Corresponding author
- Calabrese, C. R.
- ORCID
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-01-06
- Volume
- 96
- Issue
- 1
- Pages
- 56-67
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2100457669
- Cited by
- 487
- References
- 62
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 4 · 2023: 30 · 2022: 14 · 2021: 18 · 2020: 18 · 2019: 17 · 2018: 18 · 2017: 25 · 2016: 27 · 2015: 30 · 2014: 25 · 2013: 25 · 2012: 23
- FWCI
- 10.91
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- JNCI Journal of the National Cancer Institute (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Medical Research Council (G0500366)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- PARP-1 inhibitors, chemosensitization, radiosensitization, temozolomide, topotecan, irinotecan, DNA repair, DNA strand break repair, radiation damage, xenografts, drug toxicity, anticancer activity, colorectal cancer, lung cancer
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Temozolomide, Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Benzodiazepines, Carcinoma, Non-Small-Cell Lung, Dacarbazine, Enzyme Inhibitors, Gamma Rays, Humans, Lung Neoplasms, Poly(ADP-ribose) Polymerases, Radiation-Sensitizing Agents, Transplantation, Heterologous, Colorectal Neoplasms, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, Cell Line, Tumor, Mice, Azulenes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.